NCT00322803

ELB139 Given Orally to Patients With Concurrent Panic Disorder, Challenged by CO2 Inhalation After a Single Dose and One Week of Treatment

International, Multicenter, Randomized, Double-Blind, Placebo Controlled, Two-Period, Cross-Over Study to Demonstrate Safety, Tolerability and Anxiolytic Effects of 600 mg ELB139 Given Orally t.i.d. to Patients With Concurrent Panic Disorder, Challenged by Inhalation of 35% CO2 After a Single Dose and One Week of Treatment

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 24 (planned)
• Sponsor: elbion AG · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study is designed to investigate if 600 mg ELB139 given orally t.i.d. to patients suffering from panic disorder is effective in reducing anxiety evoked by inhalation of 35% CO2 measured by a visual analogue scale after the first intake and after approximately one week of treatment as compared to placebo treatment.

Conditions

• Panic Disorder

Interventions

Type	Name	Description
DRUG	ELB139

Timeline

• Start date: 2006-05-01
• Completion: 2006-10-01
• First posted: 2006-05-08
• Last updated: 2006-09-29

Locations

3 sites across 2 countries: Germany, Netherlands